i-law

Liability Risk and Insurance

The latest weight loss craze litigation

In the last three years, the diabetic drug now widely known as “Ozempic” has become a new phenomenon as an alternative route for weight loss. Following its approval for chronic weight management by the US Food and Drug Administration (FDA) in June 2021, Ozempic has since gained worldwide traction with celebrities and public figures advocating for its use.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, click Log In button.

Copyright © 2024 Maritime Insights & Intelligence Limited. Maritime Insights & Intelligence Limited is registered in England and Wales with company number 13831625 and address 5th Floor, 10 St Bride Street, London, EC4A 4AD, United Kingdom. Lloyd's List Intelligence is a trading name of Maritime Insights & Intelligence Limited.

Lloyd's is the registered trademark of the Society Incorporated by the Lloyd's Act 1871 by the name of Lloyd's.